Arzerra 1000mg Solution for Infusion

Introduction

Arzerra is a prescription medication that contains the active ingredient Ofatumumab. It is available under the brand name Arzerra. This medication is primarily used for the treatment of certain types of cancer, specifically chronic lymphocytic leukemia (CLL) and relapsed/refractory follicular lymphoma (FL).

Uses

Arzerra is prescribed to patients with chronic lymphocytic leukemia (CLL) and relapsed/refractory follicular lymphoma (FL). CLL is a type of cancer that affects the white blood cells, while follicular lymphoma is a cancer of the lymphatic system. This medication is used to help slow down the growth and spread of cancer cells in these conditions.

Dosage and Administration

The dosage of Arzerra will be determined by your healthcare provider based on various factors, including your specific medical condition, body weight, and overall health. It is typically administered as an intravenous infusion (IV) over a specific period of time. The infusion is usually given once a week for the first month, followed by once every four weeks for the remaining treatment period. Your healthcare provider will closely monitor your response to the medication and may adjust the dosage if necessary.

Mechanism of Action

Ofatumumab, the active ingredient in Arzerra, works by targeting a protein called CD20 that is found on the surface of cancerous B cells. By binding to CD20, Ofatumumab helps to destroy these cells and inhibit their growth. This mechanism of action helps to reduce the number of cancer cells in the body and slow down the progression of the disease.

Side Effects

Common side effects may include infusion-related reactions, such as fever, chills, nausea, headache, or fatigue. These reactions are usually mild to moderate in severity and can be managed with appropriate medical intervention. Serious side effects are rare but can include severe allergic reactions, infections, and low blood cell counts. If you experience any concerning or persistent side effects, seek immediate medical attention.

Drug Interactions

inform your healthcare provider about all the medications you are currently taking, including prescription drugs, over-the-counter medications, and any herbal supplements. Certain medications may interact with Arzerra, potentially affecting its effectiveness or increasing the risk of side effects. Your healthcare provider will review your medication list and adjust your treatment plan accordingly to minimize any potential interactions.

Precautions

Before starting treatment with Arzerra, inform your healthcare provider about any pre-existing medical conditions, including allergies, infections, or a history of immunization with live vaccines. This medication may not be suitable for everyone, and your healthcare provider will consider these factors when determining your treatment plan. Arzerra should not be used during pregnancy or while breastfeeding, as it may harm the developing fetus or newborn.

Storage

Arzerra should be stored in a refrigerator at a temperature between 2°C to 8°C (36°F to 46°F). Keep the medication in its original packaging, protected from light and moisture. Do not freeze the solution. If you have any unused or expired medication, dispose of it properly according to local regulations.

Patient Tips

• Follow your healthcare provider’s instructions regarding the timing and frequency of your medication infusions.
• Stay hydrated before and after the infusion to help minimize the risk of dehydration.
• Report any concerning side effects or changes in your health to your healthcare provider promptly.
• Keep all your scheduled follow-up appointments for monitoring and blood tests.
• Inform your healthcare provider about any new medications or supplements you start taking while on Arzerra.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Ofatumumab (Drugs.com) [Accessed 12 Jun. 2024] (online) Available at:
• ofatumumab 20 mg/0.4 ml subcutaneous pen injector (RX) [Accessed 18 Jun. 2024] (online) Available at:
• Ofatumumab Injection (Chronic Lymphocytic Leukemia) [Accessed 12 Jun. 2024] (online) Available at:
• Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. [Accessed 30 Jun. 2024] Available at: